A Study of Endoscopic Ethanol Ablation of Communicating Pancreatic Cystic Neoplasms


About this study

 The purpose of this study is to evaluate the effects of treating pancreas cysts that connect with the main pancreas duct with injected ethanol using endoscopic retrograde cholangiopancreatography (ERCP) and/or endoscopic ultrasound. Past studies have excluded these cysts that communicate with the main pancreatic duct, to avoid burning the main pancreatic duct with ethanol.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Presence of a pancreatic cystic lesion, at least 2 cm in maximum diameter
  • Cyst may communicate, or definitely communicates, with the pancreatic duct (based on prior CT, MR, ERCP, or EUS images)
  • Treatment of the cystic lesion is desired due to symptoms or concern for subsequent malignancy
  • Age at least 18 years
  • Able to give informed consent
  • Surgical treatment has been considered and a surgical consultation offered or the cyst does not meet consensus criteria for surgical resection
    • Current consensus criteria for resection is one or more of the following
      • Cyst is symptomatic
      • ≥ 3 cm in diameter
      • Contains a mural nodule
      • Cytology of cyst fluid is positive for malignancy
      • Main pancreatic duct diameter is > 6 mm

Exclusion Criteria

  • Known or suspected pregnancy, or nursing
  • History of pancreatitis within 3 months prior to study endoscopy procedures
  • Cyst has a primarily microcystic architecture on EUS

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Mark Topazian, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer